1. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
- Author
-
Nadine Lemaître, Jérôme Robert, N. Fortineau, C. Verdet, P. Morand, S. Gallien, O. Bouchaud, P. Sellier, K. Lacombe, Frédéric Schramm, A. Hummel, F. Mechaï, Valérie Pourcher, J.-L. Meynard, V. Delcey, J. Lourenco, J.-M. Molina, J.-W. Decousser, A. Ferroni, Christophe Rioux, T. Billard-Pomares, V. Lalande, B. Wyplosz, Dhiba Marigot-Outtandy, D. Le Dû, F. Cohen, G. Pialoux, C. Pierre-Audigier, H. Nunes, E. Catherinot, Lorenzo Guglielmetti, L. Lassel, B. Denis, M. Gominet, Nicolas Veziris, B. Crestani, V. Chambrin, Eric Caumes, L. Deconinck, R. Guéry, Yazdan Yazdanpanah, A.-L. Roux, C. Guillet, A.-L. Munier, B. Nebbad-Lechani, F. Morel, C. Le Jeunne, N. Grall, M. Lafaurie, Hugo Langris, E. Carbonnelle, E. Bille, N. Lemaitre, S. Abgrall, M. Pellan, Faiza Mougari, I. Bonnet, A.-S. Morin, P. Loulergue, Marwa Bachir, Sheila Chiesi, J. Jaffré, Alexandra Aubry, A.-L. Nardi, J. Dumoulin, S. Bulifon, C. Londner, N. Roche, M. Jachym, A. Canestri, J. Pavie, Simone Tunesi, A. Galy, N. De Castro, B. Fantin, J.D. Lelièvre, C. Dumesnil, Typhaine Billard-Pomares, E. Lecorché, Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Université de Caen Normandie (UNICAEN), Normandie Université (NU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Strasbourg, CHU Amiens-Picardie, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière] (CNR-MyRMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], and Gestionnaire, Hal Sorbonne Université
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Tuberculosis ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Antitubercular Agents ,Infectious and parasitic diseases ,RC109-216 ,Drug resistance ,World health ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Drug Resistance, Bacterial ,Epidemiology ,Isoniazid ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,drug resistance ,business.industry ,Mycobacterium tuberculosis ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Factors treatment ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,Infectious Diseases ,Streptomycin ,Case-Control Studies ,epidemiology ,Female ,France ,business ,medicine.drug - Abstract
Objectives Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.
- Published
- 2021
- Full Text
- View/download PDF